{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:43:40Z","timestamp":1790034220697,"version":"4.0.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Concerns about vaccine safety can lead to decreased acceptance of vaccines and resurgence of vaccine-preventable diseases. We summarize the key evidence on some of the main current vaccine safety controversies in the United States, including (1) measles, mumps, and rubella vaccine and autism; (2) thimerosal, a mercury-based vaccine preservative and the risk of neurodevelopmental disorders; (3) vaccine-induced Guillain-Barr\u00e9 syndrome (GBS); (4) vaccine-induced autoimmune diseases; (5) safety of human papillomavirus vaccine; (6) aluminum adjuvant-induced autoimmune diseases and other disorders; and (7) too many vaccines given early in life predisposing children to health and developmental problems. A possible small increased risk of GBS following influenza vaccination has been identified, but the magnitude of the increase is less than the risk of GBS following influenza infection. Otherwise, the biological and epidemiologic evidence does not support any of the reviewed vaccine safety concerns.<\/jats:p>","DOI":"10.1093\/cid\/ciz135","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T21:22:21Z","timestamp":1549574541000},"page":"726-731","source":"Crossref","is-referenced-by-count":72,"title":["Principal Controversies in Vaccine Safety in the United States"],"prefix":"10.1093","volume":"69","author":[{"given":"Frank","family":"DeStefano","sequence":"first","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Greorgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather Monk","family":"Bodenstab","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, The Children\u2019s Hospital of Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Offit","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Children\u2019s Hospital of Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,12]]},"reference":[{"key":"2019080101005935000_CIT0001","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(97)11096-0","article-title":"Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children","volume":"351","author":"Wakefield","year":"1998","journal-title":"Lancet"},{"key":"2019080101005935000_CIT0002","doi-asserted-by":"crossref","first-page":"c696","DOI":"10.1136\/bmj.c696","article-title":"Lancet retracts Wakefield\u2019s MMR paper","volume":"340","author":"Dyer","year":"2010","journal-title":"BMJ"},{"key":"2019080101005935000_CIT0003","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(99)01239-8","article-title":"Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association","volume":"353","author":"Taylor","year":"1999","journal-title":"Lancet"},{"key":"2019080101005935000_CIT0004","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa021134","article-title":"A population-based study of measles, mumps, and rubella vaccination and autism","volume":"347","author":"Madsen","year":"2002","journal-title":"N Engl J Med"},{"key":"2019080101005935000_CIT0005","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(04)17020-7","article-title":"MMR vaccination and pervasive developmental disorders: a case-control study","volume":"364","author":"Smeeth","year":"2004","journal-title":"Lancet"},{"key":"2019080101005935000_CIT0006","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.2015.3077","article-title":"Autism occurrence by MMR vaccine status among US children with older siblings with and without autism","volume":"313","author":"Jain","year":"2015","journal-title":"JAMA"},{"key":"2019080101005935000_CIT0007","volume-title":"Immunization safety review","author":"Immunization Safety Review Committee","year":"2004"},{"key":"2019080101005935000_CIT0008","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1016\/j.vaccine.2014.04.085","article-title":"Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies","volume":"32","author":"Taylor","year":"2014","journal-title":"Vaccine"},{"key":"2019080101005935000_CIT0009","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.290.13.1763","article-title":"Association between thimerosal-containing vaccine and autism","volume":"290","author":"Hviid","year":"2003","journal-title":"JAMA"},{"key":"2019080101005935000_CIT0010","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1542\/peds.2010-0309","article-title":"Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism","volume":"126","author":"Price","year":"2010","journal-title":"Pediatrics"},{"key":"2019080101005935000_CIT0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archgenpsychiatry.2007.1","article-title":"Continuing increases in autism reported to California\u2019s developmental services system: mercury in retrograde","volume":"65","author":"Schechter","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"2019080101005935000_CIT0012","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1542\/peds.2003-1176-L","article-title":"Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association","volume":"114","author":"Heron","year":"2004","journal-title":"Pediatrics"},{"key":"2019080101005935000_CIT0013","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMoa071434","article-title":"Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years","volume":"357","author":"Thompson","year":"2007","journal-title":"N Engl J Med"},{"key":"2019080101005935000_CIT0014","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1542\/peds.2008-0795","article-title":"Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines","volume":"123","author":"Tozzi","year":"2009","journal-title":"Pediatrics"},{"key":"2019080101005935000_CIT0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"2019080101005935000_CIT0016","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.vaccine.2015.05.013","article-title":"Guillain-Barr\u00e9 syndrome and influenza vaccines: a meta-analysis","volume":"33","author":"Mart\u00edn Arias","year":"2015","journal-title":"Vaccine"},{"key":"2019080101005935000_CIT0017","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2105\/AJPH.2013.301651","article-title":"Cumulative risk of Guillain-Barr\u00e9 syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic","volume":"104","author":"Vellozzi","year":"2014","journal-title":"Am J Public Health"},{"key":"2019080101005935000_CIT0018","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019080101005935000_CIT0019","doi-asserted-by":"crossref","first-page":"E112","DOI":"10.1542\/peds.108.6.e112","article-title":"Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus","volume":"108","author":"DeStefano","year":"2001","journal-title":"Pediatrics"},{"key":"2019080101005935000_CIT0020","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJMoa032665","article-title":"Childhood vaccination and type 1 diabetes","volume":"350","author":"Hviid","year":"2004","journal-title":"N Engl J Med"},{"key":"2019080101005935000_CIT0021","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archneur.60.4.504","article-title":"Vaccinations and risk of central nervous system demyelinating diseases in adults","volume":"60","author":"DeStefano","year":"2003","journal-title":"Arch Neurol"},{"key":"2019080101005935000_CIT0022","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200102013440502","article-title":"Hepatitis B vaccination and the risk of multiple sclerosis","volume":"344","author":"Ascherio","year":"2001","journal-title":"N Engl J Med"},{"key":"2019080101005935000_CIT0023","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200102013440501","article-title":"Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group","volume":"344","author":"Confavreux","year":"2001","journal-title":"N Engl J Med"},{"key":"2019080101005935000_CIT0024","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study","volume":"347","author":"Arnheim-Dahlstr\u00f6m","year":"2013","journal-title":"BMJ"},{"key":"2019080101005935000_CIT0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papillomavirus (HPV) vaccines: six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J Autoimmun"},{"key":"2019080101005935000_CIT0026","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"key":"2019080101005935000_CIT0027","doi-asserted-by":"crossref","first-page":"e20180943","DOI":"10.1542\/peds.2018-0943","article-title":"Primary ovarian insufficiency and adolescent vaccination","volume":"142","author":"Naleway","year":"","journal-title":"Pediatrics"},{"key":"2019080101005935000_CIT0028","volume-title":"Human papillomavirus (HPV) vaccines","author":"European Medicines Agency Assessment Report","year":"2015"},{"key":"2019080101005935000_CIT0029","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.1016\/j.vaccine.2011.09.124","article-title":"Updated aluminum pharmacokinetics following infant exposures through diet and vaccination","volume":"29","author":"Mitkus","year":"2011","journal-title":"Vaccine"},{"key":"2019080101005935000_CIT0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.acap.2017.09.003","article-title":"Blood and hair aluminum levels, vaccine history, and early infant development: a cross-sectional study","volume":"18","author":"Karwowski","year":"2018","journal-title":"Acad Pediatr"},{"key":"2019080101005935000_CIT0031","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/brain\/124.9.1821","article-title":"Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle","volume":"124","author":"Gherardi","year":"2001","journal-title":"Brain"},{"key":"2019080101005935000_CIT0032","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1016\/j.vaccine.2018.08.036","article-title":"Aluminum in vaccines: does it create a safety problem?","volume":"36","author":"Principi","year":"2018","journal-title":"Vaccine"},{"key":"2019080101005935000_CIT0033","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaut.2010.07.003","article-title":"\u2018ASIA\u2019 - autoimmune\/inflammatory syndrome induced by adjuvants","volume":"36","author":"Shoenfeld","year":"2011","journal-title":"J Autoimmun"},{"key":"2019080101005935000_CIT0034","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jaip.2017.06.033","article-title":"Evidence refuting the existence of autoimmune\/autoinflammatory syndrome induced by adjuvants (ASIA)","volume":"5","author":"Ameratunga","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2019080101005935000_CIT0035","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jaci.2011.09.007","article-title":"Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality","volume":"129","author":"Linneberg","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2019080101005935000_CIT0036","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1542\/peds.109.1.124","article-title":"Addressing parents\u2019 concerns: do multiple vaccines overwhelm or weaken the infant\u2019s immune system?","volume":"109","author":"Offit","year":"2002","journal-title":"Pediatrics"},{"key":"2019080101005935000_CIT0037","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/pr.2016.272","article-title":"Lack of broad functional differences in immunity in fully vaccinated vs. unvaccinated children","volume":"81","author":"Sherrid","year":"2017","journal-title":"Pediatr Res"},{"key":"2019080101005935000_CIT0038","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jama.2018.0708","article-title":"Association between estimated cumulative vaccine antigen exposure through the first 23 months of life and non-vaccine-targeted infections from 24 through 47 months of age","volume":"319","author":"Glanz","year":"2018","journal-title":"JAMA"},{"key":"2019080101005935000_CIT0039","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/pds.3482","article-title":"Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7\u221210\u2009years","volume":"22","author":"Iqbal","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2019080101005935000_CIT0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jpeds.2013.02.001","article-title":"Increasing exposure to antibody-stimulating proteins and polysaccharides in vaccines is not associated with risk of autism","volume":"163","author":"DeStefano","year":"2013","journal-title":"J Pediatr"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz135\/28493493\/ciz135.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/4\/726\/29022143\/ciz135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T05:01:31Z","timestamp":1564635691000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/4\/726\/5316263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,12]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,2,12]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz135","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,15]]},"published":{"date-parts":[[2019,2,12]]}}}